Fosun Pharma (02196) rose more than 3%, as of press time, up 3.47%, at HKD13.7, with a turnover of HKD41.9334 million.
According to the Zhïtong Finance APP, Fosun Pharma (02196) rose more than 3%, as of press time, up 3.47%, at HKD13.7, with a turnover of HKD41.9334 million.
In terms of news, Fosun Pharma announced that it has implemented the A-share buyback through centralized bidding trading for the first time on June 25, and repurchased a total of 1.1608 million shares of A shares (about 0.0434% of the total number of shares of the company as of June 25, 2024), with a repurchase total amount of RMB25.7226 million, a repurchase price of RMB22.16 per share, a highest price of RMB22.25 per share, and a lowest price of RMB22.03 per share.
In addition, Fosun Pharma recently announced that it plans to privatize its subsidiary Henlius through a merger and acquisition. The cash consideration for the merger and acquisition is HKD24.6 per share, with a premium of 36.67% over the closing price of Henlius H shares unaffected and a premium of 52.04% over the premium of the previous 30 trading days. The total cash consideration for the merger and acquisition does not exceed approximately HKD5.407 billion or its equivalent in RMB.